These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 31234645

  • 1. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
    De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K.
    Future Oncol; 2019 Aug; 15(23):2723-2731. PubMed ID: 31234645
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L.
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [Abstract] [Full Text] [Related]

  • 3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group.
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [Abstract] [Full Text] [Related]

  • 4. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A.
    Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
    [Abstract] [Full Text] [Related]

  • 5. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
    Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.
    J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
    [Abstract] [Full Text] [Related]

  • 6. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
    Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT.
    Oncologist; 2019 Apr; 24(4):475-482. PubMed ID: 30470690
    [Abstract] [Full Text] [Related]

  • 7. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
    Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H.
    Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
    [Abstract] [Full Text] [Related]

  • 8. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.
    JAMA Netw Open; 2019 Aug 02; 2(8):e198243. PubMed ID: 31373648
    [Abstract] [Full Text] [Related]

  • 9. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U, Shah MA.
    Expert Opin Biol Ther; 2019 Nov 02; 19(11):1135-1141. PubMed ID: 31452409
    [Abstract] [Full Text] [Related]

  • 10. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F.
    BMC Cancer; 2019 May 24; 19(1):494. PubMed ID: 31126258
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.
    Ren R, Zhang Z, Zhai S, Yang J, Tusong B, Wang J.
    Eur J Clin Pharmacol; 2024 Nov 24; 80(11):1697-1714. PubMed ID: 39102039
    [Abstract] [Full Text] [Related]

  • 12. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M.
    Invest New Drugs; 2019 Jun 24; 37(3):524-530. PubMed ID: 30687871
    [Abstract] [Full Text] [Related]

  • 13. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.
    Oncology; 2019 Jun 24; 96(5):252-258. PubMed ID: 30893708
    [Abstract] [Full Text] [Related]

  • 14. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.
    J Gastroenterol Hepatol; 2018 Apr 24; 33(4):814-824. PubMed ID: 28960444
    [Abstract] [Full Text] [Related]

  • 15. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA, RAINFALL Study Group.
    Lancet Oncol; 2019 Mar 24; 20(3):420-435. PubMed ID: 30718072
    [Abstract] [Full Text] [Related]

  • 16. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X, Zhou L, Zhou C, Shen L.
    Adv Ther; 2024 Jun 24; 41(6):2112-2132. PubMed ID: 38619719
    [Abstract] [Full Text] [Related]

  • 17. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC.
    Eur J Cancer; 2020 Sep 24; 137():272-284. PubMed ID: 32827847
    [Abstract] [Full Text] [Related]

  • 18. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
    Kim BJ, Jee HJ, Rha SY, Han HS, Ryu MH, Park SH, Kim JG, Bae WK, Lee KW, Oh DY, Byun JH, Kim DS, Suh YJ, An H, Zang DY.
    Gastric Cancer; 2022 May 24; 25(3):609-618. PubMed ID: 35015188
    [Abstract] [Full Text] [Related]

  • 19. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A, RAINBOW Investigators.
    Eur J Cancer; 2020 Mar 24; 127():150-157. PubMed ID: 32014812
    [Abstract] [Full Text] [Related]

  • 20. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
    Tehfe M, Tabchi S, Laterza MM, De Vita F.
    Future Oncol; 2018 Feb 24; 14(3):223-228. PubMed ID: 29318901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.